Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380003 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of EVT 201 to Treat Insomnia
A Phase 2 study, sponsored by Evotec Neurosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00380003 is a Phase 2 study that has completed, run by Evotec Neurosciences. The registered enrollment target is 66 participants.
The verdict
NCT00380003, a Phase 2 study, has completed, sponsored by Evotec Neurosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a compound known as EVT 201 is effective in treating people diagnosed with primary insomnia ( difficulty sleeping with no other significant contributing factor, such as depression).
Interventions
- DRUG EVT 201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00380003
The ClinicalTrials.gov registry entry for NCT00380003 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evotec Neurosciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EVT 201 is the first listed.
NCT00380003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00380003 about?
NCT00380003 is a clinical study titled "Efficacy Study of EVT 201 to Treat Insomnia". The purpose of this study is to determine whether a compound known as EVT 201 is effective in treating people diagnosed with primary insomnia ( difficulty sleeping with no other significant contributing factor, such as depression).
What is the current status of trial NCT00380003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2006-09. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00380003?
The interventions under investigation include: EVT 201 (DRUG).
Who is sponsoring clinical trial NCT00380003?
This trial is sponsored by Evotec Neurosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.